Drug Profile
Human papillomavirus vaccine - AnGes
Alternative Names: BLS-ILB-E710c; CIN therapeutic vaccine - AnGes; GLBL101c; HPV vaccine + lactobacillus carrier - AnGes/Bioleaders/GenoLac/Morishita Jintan/University of Tokyo; Oral HPV vaccine - AnGes/Bioleaders/GenoLac/Morishita Jintan/University of TokyoLatest Information Update: 31 Jan 2022
Price :
$50
*
At a glance
- Originator Bioleaders Corporation
- Developer AnGes; Bioleaders Corporation; Morishita Jintan; University of Tokyo
- Class Cancer vaccines; Papillomavirus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
Most Recent Events
- 12 Jan 2022 Immunogenicity and adverse events data from a phase IIb trial in Cervical intraepithelial neoplasia presented at the International Conference on Molecular Targets and Cancer (AACR-NCI-EORTC-2021)
- 03 Jan 2020 AnGes MG is now called AnGes
- 30 Aug 2017 Phase-II clinical trials in Cervical intraepithelial neoplasia in South Korea (PO) (NCT03274206)